Real-world efficacy and safety of pembrolizumab in patients with non-small cell lung cancer: a retrospective observational study - Archive ouverte HAL Access content directly
Journal Articles Tumori Year : 2021

Real-world efficacy and safety of pembrolizumab in patients with non-small cell lung cancer: a retrospective observational study

(1) , (1) , (2, 3) , (4, 5) , (1) , (2, 3) , (2, 3) , (1, 6)
1
2
3
4
5
6

Abstract

Background: Pembrolizumab, a humanized immunoglobulin monoclonal antibody directed against the programmed cell death 1 receptor, demonstrated robust efficacy and a manageable safety profile across multiple tumor types in clinical trials. Aim: To investigate the efficacy and safety of first-line pembrolizumab for patients with non-small cell lung cancers (NSCLCs) in clinical practice. Methods: In this observational monocentric retrospective study, 38 patients with PD-L1 >50% were enrolled between November 2017 and November 2018. Results: The global median overall survival was 11.08 months (95% confidence interval [CI], 5.98-not reached) and the global median progression-free survival was 6 months (95% CI, 3-not reached). In the univariate analysis, clinical performance status score and the development of immune-related adverse events were the only 2 clinical factors significantly correlated with overall survival. Conclusion: The results of the present study suggest that pembrolizumab seems less effective in the real-life population than in the pivotal clinical trials in patients with NSCLC but remains an effective treatment option for patients with NSCLC. Longer follow-up is needed.
Embargoed file
Embargoed file
Ne sera jamais visible

Dates and versions

inserm-03090453 , version 1 (13-05-2022)

Identifiers

Cite

François Cavaille, Mathieu Peretti, Marie Eve Garcia, Roch Giorgi, Nathalie Ausias, et al.. Real-world efficacy and safety of pembrolizumab in patients with non-small cell lung cancer: a retrospective observational study. Tumori, 2021, 107 (1), pp.32-38. ⟨10.1177/0300891620926244⟩. ⟨inserm-03090453⟩
78 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More